Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Daniel Rayson; Sasha Lupichuk; Kylea Potvin; Susan Dent; Tamara Shenkier; Sukhbinder Dhesy-Thind; Susan L. Ellard; Catherine Prady; Muhammad Salim; Patricia Farmer; Ghasson Allo; Ming Sound Tsao; Alison Allan; Olga Ludkovski; Maria Bonomi; Dongsheng Tu; Linda Hagerman; Rachel Goodwin; Elizabeth Eisenhauer; Penelope Bradbury

doi:10.1007/s10549-016-3812-1

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Daniel Rayson, Sasha Lupichuk, Kylea Potvin, Susan Dent, Tamara Shenkier, Sukhbinder Dhesy-Thind, Susan L. Ellard, Catherine Prady, Muhammad Salim, Patricia Farmer, Ghasson Allo, Ming Sound Tsao, Alison Allan, Olga Ludkovski, Maria Bonomi, Dongsheng Tu, Linda Hagerman, Rachel Goodwin, Elizabeth Eisenhauer, Penelope Bradbury

Research output: Contribution to journal › Article › peer-review

40 Citations (Scopus)

Original language	English
Pages (from-to)	109-116
Number of pages	8
Journal	Breast Cancer Research and Treatment
Volume	157
Issue number	1
DOIs	https://doi.org/10.1007/s10549-016-3812-1
Publication status	Published - May 1 2016
Externally published	Yes

ASJC Scopus Subject Areas

Oncology
Cancer Research

Keywords

Clinical activity
Foretinib
MET targeting
Triple-negative breast cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10549-016-3812-1

Fingerprint

Dive into the research topics of 'Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer'. Together they form a unique fingerprint.

Cite this

Rayson, D., Lupichuk, S., Potvin, K., Dent, S., Shenkier, T., Dhesy-Thind, S., Ellard, S. L., Prady, C., Salim, M., Farmer, P., Allo, G., Tsao, M. S., Allan, A., Ludkovski, O., Bonomi, M., Tu, D., Hagerman, L., Goodwin, R., Eisenhauer, E., & Bradbury, P. (2016). Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Research and Treatment, 157(1), 109-116. https://doi.org/10.1007/s10549-016-3812-1

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. / Rayson, Daniel; Lupichuk, Sasha; Potvin, Kylea et al.
In: Breast Cancer Research and Treatment, Vol. 157, No. 1, 01.05.2016, p. 109-116.

Research output: Contribution to journal › Article › peer-review

Rayson, D, Lupichuk, S, Potvin, K, Dent, S, Shenkier, T, Dhesy-Thind, S, Ellard, SL, Prady, C, Salim, M, Farmer, P, Allo, G, Tsao, MS, Allan, A, Ludkovski, O, Bonomi, M, Tu, D, Hagerman, L, Goodwin, R, Eisenhauer, E & Bradbury, P 2016, 'Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer', Breast Cancer Research and Treatment, vol. 157, no. 1, pp. 109-116. https://doi.org/10.1007/s10549-016-3812-1

Rayson D, Lupichuk S, Potvin K, Dent S, Shenkier T, Dhesy-Thind S et al. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Research and Treatment. 2016 May 1;157(1):109-116. doi: 10.1007/s10549-016-3812-1

@article{a962268e0e184a6cbbd6d168fcd42b9b,

title = "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer",

keywords = "Clinical activity, Foretinib, MET targeting, Triple-negative breast cancer",

author = "Daniel Rayson and Sasha Lupichuk and Kylea Potvin and Susan Dent and Tamara Shenkier and Sukhbinder Dhesy-Thind and Ellard, {Susan L.} and Catherine Prady and Muhammad Salim and Patricia Farmer and Ghasson Allo and Tsao, {Ming Sound} and Alison Allan and Olga Ludkovski and Maria Bonomi and Dongsheng Tu and Linda Hagerman and Rachel Goodwin and Elizabeth Eisenhauer and Penelope Bradbury",

note = "Publisher Copyright: {\textcopyright} 2016, Springer Science+Business Media New York.",

year = "2016",

month = may,

day = "1",

doi = "10.1007/s10549-016-3812-1",

language = "English",

volume = "157",

pages = "109--116",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "1",

}

TY - JOUR

T1 - Canadian Cancer Trials Group IND197

T2 - a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

AU - Rayson, Daniel

AU - Lupichuk, Sasha

AU - Potvin, Kylea

AU - Dent, Susan

AU - Shenkier, Tamara

AU - Dhesy-Thind, Sukhbinder

AU - Ellard, Susan L.

AU - Prady, Catherine

AU - Salim, Muhammad

AU - Farmer, Patricia

AU - Allo, Ghasson

AU - Tsao, Ming Sound

AU - Allan, Alison

AU - Ludkovski, Olga

AU - Bonomi, Maria

AU - Tu, Dongsheng

AU - Hagerman, Linda

AU - Goodwin, Rachel

AU - Eisenhauer, Elizabeth

AU - Bradbury, Penelope

PY - 2016/5/1

Y1 - 2016/5/1

KW - Clinical activity

KW - Foretinib

KW - MET targeting

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84969864747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969864747&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-3812-1

DO - 10.1007/s10549-016-3812-1

M3 - Article

C2 - 27116183

AN - SCOPUS:84969864747

SN - 0167-6806

VL - 157

SP - 109

EP - 116

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

ASJC Scopus Subject Areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this